Results 31 to 40 of about 547,171 (369)
A redox-responsive hyaluronic acid-based hydrogel for chronic wound management [PDF]
, 2021 Polymer-based hydrogels have been widely applied for chronic wound therapeutics, due to their well-acclaimed wound exudate management capability. At the same time, there is still an unmet clinical need for simple wound diagnostic tools to assist clinical decision-making at the point of care and deliver on the vision of patient-personalised wound ...
arxiv +1 more source
International Journal of Molecular Sciences, 2020 The bone-derived hormone fibroblast growth factor 23 (FGF23) acts in concert with parathyroid hormone (PTH) and the active vitamin D metabolite calcitriol in the regulation of calcium (Ca) and phosphate (P) homeostasis.
M. Mace, K. O̸lgaard, E. Lewin
semanticscholar +1 more source
Fibroblast Growth Factor–23 and Cardiac Structure and Function [PDF]
, 2014 Background: Fibroblast growth factor–23 (FGF‐23) is a phosphaturic factor previously associated with left ventricular hypertrophy and systolic dysfunction among individuals with chronic kidney disease.
Agarwal, Isha +7 more
core +1 more source
ESC Heart Failure, 2020 Besides regulating calcium‐phosphate metabolism, fibroblast growth factor 23 (FGF‐23) has been associated with incident heart failure (HF) and left ventricular hypertrophy.
C. Roy +16 more
semanticscholar +1 more source
Iron and fibroblast growth factor 23 in X-linked hypophosphatemia [PDF]
, 2014 Background Excess fibroblast growth factor 23 (FGF23) causes hypophosphatemia in autosomal dominant hypophosphatemic rickets (ADHR) and X-linked hypophosphatemia (XLH). Iron status influences C-terminal FGF23 (incorporating fragments plus intact FGF23)
Econs, Michael J. +3 more
core +1 more source
Serum intact fibroblast growth factor 23 in healthy paediatric population
Open Medicine, 2021 It is believed that fibroblast growth factor 23 (FGF23) can become an early biomarker of chronic kidney disease progression. Data on FGF23 age dependency are inconsistent.
Stanczyk Malgorzata +3 more
doaj +1 more source
Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis [PDF]
, 2019 Background: Etelcalcetide is an intravenous calcimimetic approved for treatment of secondary hyperparathyroidism (sHPT) in patients receiving hemodialysis. Besides lowering parathyroid hormone (PTH), etelcalcetide also significantly reduces fibroblast
Block, Geoffrey A. +9 more
core +1 more source
Update on fibroblast growth factor 23 in chronic kidney disease [PDF]
, 2012 Chronic kidney disease (CKD) is a public health epidemic that affects millions of people worldwide. Presence of CKD predisposes individuals to high risks of end-stage renal disease (ESRD), cardiovascular disease, and premature death. Disordered phosphate
Wolf, Myles
core +1 more source
Fibroblast Growth Factor-23—A Potential Uremic Toxin
Toxins, 2016 Fibroblast growth factor-23 (FGF23) is a circulating member of the FGF family produced mainly by the osteocytes and osteoblasts that can act as a hormone.
Piotr Kuczera +2 more
doaj +1 more source
Comparison of particle-size analyzing laboratory methods [PDF]
, 2015 Patients with chronic renal failure are known to have renal osteodystrophy (bone disease) and increased calcification of vessels. A new marker of bone disease, sclerostin, the two pro-inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha) and ...
Barta, Károly +6 more
core +1 more source